Search - tctmd.com

Displaying 21 - 40 of 78

Sort: Relevancy | Date

News Daily News

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

L.A. McKeown

December 13, 2024

News Daily News

Could Pricey GLP-1 Drugs Cut Healthcare Costs? The Math Isn’t Simple

L.A. McKeown

December 09, 2024

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

News Daily News

Defying Earlier GLP-1 Data, Study in Teens Sees Possible Mental Health Gains

L.A. McKeown

October 22, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

Caitlin E. Cox

September 03, 2024

News Daily News

Childhood Risk Factors Predict Later CVD Risk

L.A. McKeown

June 28, 2024

News Daily News

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

L.A. McKeown

June 05, 2024

News Conference News ACC 2024

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

L.A. McKeown

April 11, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

L.A. McKeown

February 01, 2024

News Daily News

Counting Quality, Not Carbs, May Be Key to Weight Management

L.A. McKeown

January 05, 2024

News Opinion CV Team Dispatch

January 2024 Dispatch for the CV Team

L.A. McKeown

January 01, 2024

News Daily News

Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose

L.A. McKeown

December 01, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

L.A. McKeown

October 10, 2023

News Conference News ADA 2023

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

L.A. McKeown

June 28, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

Regaining Weight Won’t Erode CV Risk Factor Benefits Short Term

L.A. McKeown

March 31, 2023

Advertisement

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

Could Pricey GLP-1 Drugs Cut Healthcare Costs? The Math Isn’t Simple

November 2024 Dispatch for the CV Team

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

Defying Earlier GLP-1 Data, Study in Teens Sees Possible Mental Health Gains

TCTMD’s Top 10 Most Popular Stories for August 2024

Childhood Risk Factors Predict Later CVD Risk

As Trends Reverse in CVD, AHA Warns of Soaring Costs and Illness

BE ACTIVE: Gaming for Points and Money Can Boost Step Counts

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

February 2024 Dispatch for the CV Team

Counting Quality, Not Carbs, May Be Key to Weight Management

January 2024 Dispatch for the CV Team

Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose

FDA Grants Tirzepatide a New Indication for Obesity Management

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

Regaining Weight Won’t Erode CV Risk Factor Benefits Short Term

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content